Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 8Rhabdomyosarcoma 8Wilms Tumor 7Malignant mesenchymal tumor 5Kidney Neoplasms 4Rhabdomyosarcoma, Embryonal 3Neuroectodermal Tumors, Primitive, Peripheral 3Rhabdomyosarcoma, Alveolar 2Hydatidiform Mole 2Gestational Trophoblastic Disease 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Ewing 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Lymphoma 1Liposarcoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Choroid Plexus Neoplasms 1Choriocarcinoma 1Brain Neoplasms 1Blast Crisis 1Beckwith-Wiedemann Syndrome 1

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pleuropulmonary blastoma × Dactinomycin × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡